123 related articles for article (PubMed ID: 26725705)
1. A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
Mihaila RG
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):519-26. PubMed ID: 26725705
[TBL] [Abstract][Full Text] [Related]
2. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
Man CH; Lam SS; Sun MK; Chow HC; Gill H; Kwong YL; Leung AY
Blood; 2014 Apr; 123(16):2530-9. PubMed ID: 24608976
[TBL] [Abstract][Full Text] [Related]
3. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
[TBL] [Abstract][Full Text] [Related]
5. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
Huang A; Ju HQ; Liu K; Zhan G; Liu D; Wen S; Garcia-Manero G; Huang P; Hu Y
Cancer Lett; 2016 Jul; 377(2):149-57. PubMed ID: 27132990
[TBL] [Abstract][Full Text] [Related]
6. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
Wang F; Liu Z; Zeng J; Zhu H; Li J; Cheng X; Jiang T; Zhang L; Zhang C; Chen T; Liu T; Jia Y
Leuk Res; 2015 Dec; 39(12):1421-7. PubMed ID: 26505133
[TBL] [Abstract][Full Text] [Related]
7. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
[No Abstract] [Full Text] [Related]
9. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
10. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
Mohan BP; How GF; Loh Y; Linn YC
Br J Haematol; 2012 Apr; 157(1):131-2. PubMed ID: 22050655
[No Abstract] [Full Text] [Related]
12. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Zhao R; Follows GA; Beer PA; Scott LM; Huntly BJ; Green AR; Alexander DR
N Engl J Med; 2008 Dec; 359(26):2778-89. PubMed ID: 19109573
[TBL] [Abstract][Full Text] [Related]
14. Targeted signal transduction therapies in myeloid malignancies.
Scott E; Hexner E; Perl A; Carroll M
Curr Oncol Rep; 2010 Nov; 12(6):358-65. PubMed ID: 20809224
[TBL] [Abstract][Full Text] [Related]
15. Na+/H+ exchanger inhibitor augments hyperosmolarity-induced vasoconstriction by enhancing actin polymerization.
Sasahara T; Yayama K; Tahara T; Onoe H; Okamoto H
Vascul Pharmacol; 2013; 59(5-6):120-6. PubMed ID: 23872622
[TBL] [Abstract][Full Text] [Related]
16. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
[TBL] [Abstract][Full Text] [Related]
18. Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger.
Jin W; Li Q; Lin Y; Lu Y; Li H; Wang L; Hu R; Ma L; Wang J; Pang T
Cancer Lett; 2011 Sep; 308(1):81-90. PubMed ID: 21576001
[TBL] [Abstract][Full Text] [Related]
19. Cariporide inhibits high glucose-mediated adhesion of monocyte-endothelial cell and expression of intercellular adhesion molecule-1.
Wang SX; Sun XY; Zhang XH; Chen SX; Liu YH; Liu LY
Life Sci; 2006 Aug; 79(14):1399-404. PubMed ID: 16720033
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone increases fluid absorption via Na+/H+ exchanger (NHE) 3 activation in normal human middle ear epithelial cells.
Choi JY; Kim SY; Son EJ; Kim JL; Shin JH; Song MH; Moon UY; Yoon JH
Eur J Pharmacol; 2006 Apr; 536(1-2):12-8. PubMed ID: 16564041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]